Key result
Arachidonic acid at 1.6 mM reproducibly induced platelet aggregation in 26 healthy volunteers without overcoming the antiplatelet effect of 6 daily doses of 81 mg aspirin.
Why the study?
What concentration of arachidonic acid reliably induces ex vivo platelet aggregation without overcoming the inhibitory effect of low-dose aspirin?
Population
Healthy volunteers (n=26 for the aspirin phase)
Comparison
Arachidonic acid at 1.6 mM concentration ex… vs Varying concentrations of AA; baseline…
Design
Other
Follow-up
6 days
Authors
Loading...
1.6 mM arachidonic acid may aid ex vivo aspirin monitoring; hypothesis-generating and requires validation in patients.
What concentration of arachidonic acid reliably induces ex vivo platelet aggregation without overcoming the inhibitory effect of low-dose aspirin?
Effect estimate: 1.5 mM (95% CI 1.1-2.1)
A concentration of 1.6 mM arachidonic acid is optimal for ex vivo platelet aggregation testing, as it reliably induces aggregation without overriding the effects of low-dose aspirin.
Burke et al. (2003) studied Healthy volunteers (n=26). Arachidonic acid and Aspirin was evaluated on Arachidonic acid concentration estimated to aggregate platelets from ≥90% of subjects (1.5 mM, 95% CI 1.1-2.1). Arachidonic acid at 1.6 mM reproducibly induced platelet aggregation in 26 healthy volunteers without overcoming the antiplatelet effect of 6 daily doses of 81 mg aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: